Seqirus, GlaxoSmithKline to Produce Flu Vaccine Vials for US Military, Civilian Agencies

Seqirus and GlaxoSmithKline have each won a contract worth $18.1 million and $17.1 million, respectively, from the Defense Logistics Agency to manufacture multi-dose influenza vaccine vials.

The pharmaceutical companies will produce the vials for the U.S. Army, Navy, Air Force, Marine Corps and federal civilian agencies under their one-year contracts, the Defense Department said Wednesday.

Work under the contract will occur in Pennsylvania and Australia through June 7, 2017 and DLA used its fiscal 2016 and fiscal 2017 defense working capital funds for the acquisition effort.

DLA received four offers for the program during a competitive acquisition process.